Jump to content

Kyowa Kirin

From Wikipedia, the free encyclopedia

This is an old revision of this page, as edited by Yobot (talk | contribs) at 07:51, 3 December 2016 (External links: Removed invisible unicode characters + other fixes, removed: ‎ using AWB). The present address (URL) is a permanent link to this revision, which may differ significantly from the current revision.

Kyowa Hakko Kirin Co., Ltd.
Company typePublic KK
TYO: 4151
FWBKY4
Nikkei 225 Component
Industry
FoundedJuly 1, 1949
HeadquartersOhtemachi Building, 1-6-1, Ōtemachi, Chiyoda-ku, Tokyo 100-8185, Japan
Key people
Nobuo Hanai, (CEO and President)
Products
Revenue$ 3.548 billion USD (FY 2013) Increase (¥ 340.61 billion JPY) (FY 2013)
$ 31.32 million USD (FY 2013) Increase (¥ 30.07 billion JPY) (FY 2013)
Number of employees
7,152 (consolidated) (as of December 31, 2013)
ParentKirin Holdings Company, Limited
Subsidiaries47 (33 in Japan and 14 overseas countries)
WebsiteOfficial website
Footnotes / references
[1][2][3]

Kyowa Hakko Kirin Co., Ltd. (協和発酵キリン株式会社, Kyōwa Hakkō Kirin Kabushiki Kaisha) is a Japanese pharmaceutical and biotechnology company under the Kirin Holdings, and is among the 40 largest in the world by revenue. The company is headquartered in Chiyoda-ku, Tokyo and is a member of the Nikkei 225 stock index.[4][5]

History

On July 1, 1949 the forerunner of the present company, Kyowa Hakko Kogyo Co., Ltd. is established. Following the merger with Kirin Pharma Co., Ltd., on October 1, 2008 the company changed its name to its present.

On July 11, 2014, the KHK subsidiary, ProStrakan Group, acquired Archimedes Pharma from the Novo Nordisk Foundation for $394 million [6]

Business segments and products

References

  1. ^ "Kyowa Hakko Kirin Company Overview". Kyowa Hakko Kirin. Retrieved March 14, 2014.
  2. ^ "Kyowa Hakko Kirin Corporate Profile" (PDF). Kyowa Hakko Kirin. Retrieved March 14, 2014.
  3. ^ "Kyowa Hakko Kirin Annual Report 2012". Kyowa Hakko Kirin. Retrieved March 14, 2014.
  4. ^ "Components:Nikkei Stock Average". Nikkei Inc. Retrieved January 20, 2015.
  5. ^ "Top 50 Pharma Companies by 2012 Revenue". Wildwood Ventures Ltd. Retrieved March 14, 2014.
  6. ^ "ProStrakan Acquires Archimedes Pharma for $394M". Genetic Engineering & Biotechnology News. Mary Ann Liebert, Inc. July 11, 2014. Retrieved January 20, 2015.
  7. ^ "FY 2013 Consolidated Financial Summary". Kyowa Hakko Kirin. Retrieved March 14, 2014.